Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

ESMO updates precision oncology framework to improve targeted therapies (opens in a new tab)

news-medical.net · 2026-10-22

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3

The source study

The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology

Annals of Oncology · 2026
Open source record (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 5Not checkedESMO has published version 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), an updated precision oncology framework that helps oncologists assess the clinical relevance of molecular alterations and match patients with targeted therapies.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 5Not checkedESCAT v2 retains the core principles of the original scale but adds refinements, including a restructured Tier I, formal criteria for tumor-agnostic therapies, more guidance on prospective and real-world evidence, and refined lower tiers.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 5Not checkedThe new framework introduces what is believed to be the first systematic, evidence-based resistance scale developed independently of regulatory approvals, allowing clinicians to classify biomarkers linked to reduced or absent treatment benefit.View evidenceHide evidence

As statedwhat is believed to be the first

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 5Not checkedThe updated framework is intended for integration into molecular diagnostic reports, molecular tumor board discussions, clinical practice guidelines, and everyday treatment planning.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 5Not checkedThe paper was published in Annals of Oncology, and the first author quoted is Dr. Aya El Helali.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology

Annals of Oncology · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 39 candidate papers

Selected

The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology

Annals of Oncology · 2026 · Crossref

Source (opens in a new tab)
Candidate

172eP Chemotherapy in older adults with colon cancer: Real-world feasibility and tolerance in a predominantly young Moroccan setting

Annals of Oncology · 2026 · Crossref

Source (opens in a new tab)

And 33 more candidates considered.